Outrun Therapeutics Raises $10M in Seed Funding to Expand Operations and Develop Research

Outrun Therapeutics' Seed Funding

Key Highlights:

• Seed Funding: Outrun Therapeutics, a developer of E3 ligase inhibitors and protein stabilisation technologies, raised $10 million in seed funding.
• Investors: Backed by M Ventures and MP Healthcare Venture Management.
• Expansion and R&D: The funding will be used to expand operations and further develop Outrun's research and development sector.

Outrun Therapeutics' Target Market

• Target Market: Pharmaceutical and biotechnology companies focused on developing small molecule drugs targeting E3 ligases.
• Drug Discovery and Development: Organizations seeking innovative approaches to protein stabilisation and E3 ligase inhibition for the treatment of various diseases.
• Therapeutic Areas: Outrun's technologies have potential applications in disease areas where protein imbalance plays a role.

What Outrun Therapeutics Needs to Buy

• Research and Development Partnerships: Collaborations with academic institutions and research organizations to advance their understanding of E3 ligase biology and protein-to-protein interactions.
• Drug Discovery Tools and Technologies: Investments in technologies and platforms that enable the discovery and development of small molecule drugs targeting E3 ligases.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers and suppliers to ensure efficient production and distribution of their therapeutic candidates.